Heparin-Induced Thrombocytopenia in a Nonthrombocytopenic Patient With Toxic Epidermal Necrolysis Causing Fatal Outcome: Is HIT Still a HIT?

被引:1
|
作者
Busche, Marc Nicolai [1 ]
Peters, Tina [1 ]
Knobloch, Karsten [1 ]
Vogt, Peter Maria [1 ]
Rennekampff, Hans-Oliver [1 ]
机构
[1] Hannover Med Sch, Dept Plast Hand & Reconstruct Surg, Burn Ctr, D-30625 Hannover, Germany
关键词
MOLECULAR-WEIGHT HEPARIN; ARGATROBAN ANTICOAGULATION; UNFRACTIONATED HEPARIN; ANTIBODIES; THROMBOSIS; PLATELET-FACTOR-4; REPLACEMENT; THERAPY; RISK;
D O I
10.1097/BCR.0b013e3181ac05bf
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The definition of heparin-induced thrombocytopenia (HIT) has been modified over time; however, most definitions require a relative or absolute thrombocytopenia after exposure to heparin. Therefore, routine platelet count monitoring has been recommended for screening. We present the case of a 26-year-old male patient with toxic epidermal necrolysis who developed a rapid and fatal clinical presentation of HIT, without thrombocytopenia at the time of diagnosis. Because our patient did not present a relative or absolute thrombocytopenia at the time of serological and clinical confirmation of HIT, routine platelet count monitoring failed to detect HIT in our patient. As a result of the here presented case of rapid and fatal HIT, it may be prudent to consider if thrombocytopenia, although it is still a common and important hallmark of HIT, should be an absolute requirement for the definition of HIT. In cases of HIT without any thrombocytopenia, screening for HIT antibodies may be the only way to detect HIT early enough to react. Because there is a high incidence of HIT antibodies in the general population, which are not always associated with HIT, screening for HIT antibodies cannot be recommended for every patient receiving heparin. However, prospective studies may be useful in determining if routine screening for HIT antibodies can decrease the morbidity and mortality of HIT in critically ill patients receiving therapeutic doses of unfractionated heparin on the intensive care unit. (J Burn Care Res 2009;30: 747-751)
引用
收藏
页码:747 / 751
页数:5
相关论文
共 50 条
  • [1] Heparin-induced thrombocytopenia (HIT)
    Evans, Natalie S.
    Gomes, Marcelo
    VASCULAR MEDICINE, 2017, 22 (04) : 353 - 355
  • [2] The Use of Flow Cytometry in the Diagnosis of Heparin-Induced Thrombocytopenia (HIT)
    Malicev, Elvira
    TRANSFUSION MEDICINE REVIEWS, 2020, 34 (01) : 34 - 41
  • [4] Heparin-induced thrombocytopenia (HIT) in 2011: An epidemic of overdiagnosis
    Cuker, Adam
    THROMBOSIS AND HAEMOSTASIS, 2011, 106 (06) : 993 - 994
  • [5] Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT)
    Rauova, Lubica
    Arepally, Gowthami
    Poncz, Mortimer
    Cines, Douglas B.
    AUTOIMMUNITY REVIEWS, 2018, 17 (10) : 1046 - 1052
  • [6] ET gets HIT - thrombocytotic heparin-induced thrombocytopenia (HIT) in a patient with essential thrombocythemia (ET)
    Risch, L
    Pihan, H
    Zeller, C
    Huber, AR
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (07) : 663 - 667
  • [7] Comparing the incidence of heparin-induced thrombocytopenia (HIT) in patients receiving heparin (UHF) and enoxaparin (LMWH).
    Motie, Mohammad Reza
    Kazemzadeh, Gholamhossein
    Gazeran, Sahar
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (05): : 2002 - 2007
  • [8] Heparin-induced thrombocytopenia type II (HIT II). A medical-economic view
    Riedel, R.
    Schmieder, A.
    Koster, A.
    Kim, S.
    Baumgarten, G.
    Schewe, J. C.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2017, 112 (04) : 334 - 346
  • [9] Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management
    Hogan, Marie
    Berger, Jeffrey S.
    VASCULAR MEDICINE, 2020, 25 (02) : 160 - 173
  • [10] Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis
    Alving, BM
    Krishnamurti, C
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (06) : 569 - 574